胰岛素注射装置市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

Insulin Delivery Devices Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

出版日期: 2025年09月11日 | 出版商:

Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2024 年全球胰岛素输送装置市值为 228 亿美元，预计到 2034 年将以 10.4% 的复合年增长率成长至 616 亿美元。

这一强劲增长的动力源于全球糖尿病患病率的上升、技术的不断进步以及人们对疾病自我管理意识的不断增强。患者越来越需要使用者友善、便携且精准的胰岛素给药方案，包括胰岛素笔、胰岛素帮浦和胰岛素贴片，以便更好地管理血糖水平。此外，全球卫生组织和各国政府正透过致力于改善糖尿病照护的倡议，在加速市场扩张方面发挥着至关重要的作用。例如，世界卫生组织的《全球糖尿病契约》旨在降低糖尿病风险，并确保所有患者都能获得负担得起的优质治疗。胰岛素给药装置是安全有效注射胰岛素的重要工具，当人体无法自然产生足够的胰岛素时，它可以帮助患者维持适当的血糖水平。技术创新仍是推动市场成长的重要因素，各公司透过整合人体工学手柄、预充式药筒和自动给药等功能，提升了设备的舒适性、安全性和易用性。蓝牙和行动应用程式连接等数位技术的整合，为患者和医疗保健提供者提供了即时胰岛素治疗资料，从而实现了更个人化和高效的管理。

市场范围
起始年份	2024
预测年份	2025-2034
起始值	228亿美元
预测值	616亿美元
复合年增长率	10.4%

胰岛素给药设备市场在2024年占据了73.5%的市场份额，这得益于其先进的技术、耐用性以及日益受到患者和医护人员的青睐。此领域包括胰岛素笔、胰岛素帮浦等设备，旨在提供精准、便利且用户友善的胰岛素给药。这些设备因其易用性、便携性以及与数位健康平台连接的能力而广受欢迎，使其成为独立糖尿病管理不可或缺的工具。这些设备有助于最大限度地减少给药错误，并提高整体治疗效果。

预计到2034年，家庭护理市场规模将达到307亿美元，这得益于越来越多的患者选择在家中舒适地管理糖尿病。易于使用的设备的普及、自我照顾意识的增强以及公共卫生机构的支持性政策，都助长了这一趋势。患者更青睐便携式胰岛素注射装置，因为它们可以简化日常治疗流程并减少就诊次数。一次性胰岛素笔和穿戴式胰岛素帮浦以其便捷可靠而闻名，由于其培训要求低，在家庭环境中尤其受欢迎。

2024年，北美胰岛素注射装置市场占据41.6%的市场份额，这得益于其高糖尿病盛行率、先进的医疗基础设施以及强有力的监管支持。该地区的医疗保健系统注重精准性、安全性和使用者友善性，这使得胰岛素笔成为住院和门诊患者的首选。这些装置透过医院药局、零售店和线上平台广泛普及，加上保险覆盖和政府支持，进一步加速了其普及。

胰岛素给药装置市场的主要参与者包括 Biocon、Novo Nordisk、Becton Dickinson and Company、Medtronic plc、Eli Lilly & Company、Insulet Corporation、Terumo Corporation、B. Braun Melsungen AG、Sanofi、Haselmeier、Ypsomed Holdings、东宝药业、Julphar Corporation、Tandem、Deifical Corporation、Owenm、Ouk、 Corporation、Gan & Lee Pharmaceuticals、苏州鹏业医疗器材、Pacetronix 和 MicroPort。胰岛素给药装置市场的公司专注于几项核心策略，以加强其市场地位并扩大其全球影响力。持续投资于研发至关重要，这样才能推出具有增强可用性、安全性和连接功能（例如 AI 驱动的剂量和远端监控）的创新产品。扩大分销管道，包括与医疗保健提供者、药局和数位健康平台建立合作伙伴关係，有助于提高全球产品的可及性。

产业生态系统分析
- 供应商格局
- 影响价值链的因素
产业衝击力
- 成长动力
  - 糖尿病盛行率上升
  - 胰岛素输送装置的技术进步
  - 糖尿病照护支出增加
  - 优惠的设备保险和报销政策
  - 采取便利措施
- 产业陷阱与挑战
  - 胰岛素输送装置成本高
  - 发展中国家的自付费用高
  - 严格的政府法规
- 市场机会
- 与数位健康平台整合
- 智慧及穿戴式装置开发
成长潜力分析
监管格局
技术格局
- 当前的技术趋势
- 新兴技术
未来市场趋势
2024年定价分析
专利分析
报销场景
波特的分析
PESTEL分析

第四章：竞争格局

介绍
公司市占率分析
- 全球的
- 北美洲
- 欧洲
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
关键进展
- 併购
- 伙伴关係与协作
- 新产品发布
- 扩张计划

第五章：市场估计与预测：按产品，2021 - 2034 年

主要趋势
胰岛素输送装置
- 胰岛素帮浦
  - 管式帮浦
  - 无内胎帮浦
- 钢笔
  - 可重复使用的
  - 一次性的
- 其他胰岛素输送装置
耗材
- 测试条
- 笔针
  - 标准
  - 安全
- 注射器
- 胰岛素帮浦耗材

第六章：市场估计与预测：依最终用途，2021 - 2034 年

主要趋势
医院和诊所
居家护理
其他最终用户

第七章：市场估计与预测：按地区，2021 - 2034

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋

第八章：公司简介

B. Braun Melsungen AG
Becton, Dickinson and Company
Biocon
Debiotech SA
Dongbao Pharmaceutical
Eli Lilly & Company
F. Hoffmann-La Roche Ltd.
Gan & Lee Pharmaceuticals
Haselmeier
Insulet Corporation
Julphar
Lenomed Medical
Medtronic plc
MicroPort
Nipro Corporation
Novo Nordisk
Owen Mumford
Sanofi
Scientific Corporation
Suzhou Peng Ye Medical Devices
Tandem Diabetes Care
Terumo Corporation
ViCentra BV
Wockhardt Ltd.
Ypsomed Holdings

简介目录

Product Code: 1649

The Global Insulin Delivery Devices Market was valued at USD 22.8 billion in 2024 and is estimated to grow at a CAGR of 10.4% to reach USD 61.6 billion by 2034.

This robust growth is driven by the increasing prevalence of diabetes worldwide, continuous advancements in technology, and greater awareness around self-management of the disease. Patients are increasingly demanding user-friendly, portable, and accurate insulin delivery options, including insulin pens, pumps, and patch devices, to better manage their glucose levels. Furthermore, global health organizations and national governments are playing a vital role in accelerating market expansion through initiatives focused on improving diabetes care. The World Health Organization's Global Diabetes Compact, for example, aims to reduce diabetes risk and ensure that all patients have access to affordable, quality treatment. Insulin delivery devices are essential tools designed to administer insulin safely and effectively, helping individuals maintain proper blood sugar levels when their bodies cannot produce enough insulin naturally. Technological innovation remains a significant factor propelling market growth, with companies enhancing device comfort, safety, and ease of use by incorporating features such as ergonomic grips, prefilled cartridges, and automated dosing. The integration of digital technologies like Bluetooth and mobile app connectivity is providing patients and healthcare providers with real-time insulin therapy data, enabling more personalized and efficient management.

Market Scope
Start Year	2024
Forecast Year	2025-2034
Start Value	$22.8 billion
Forecast Value	$61.6 billion
CAGR	10.4%

The insulin delivery device segment held 73.5% share in 2024, owing to its advanced technology, durability, and increasing preference among both patients and healthcare professionals. This segment includes devices such as insulin pens, pumps, and others, all designed to provide precise, convenient, and user-friendly insulin administration. Their popularity stems from ease of use, portability, and the ability to connect with digital health platforms, making them indispensable tools for independent diabetes management. These devices help minimize dosing errors and enhance overall treatment outcomes.

The home care segment is anticipated to reach USD 30.7 billion by 2034, fueled by a growing number of patients choosing to manage diabetes within the comfort of their own homes. The availability of easy-to-use devices, increased awareness of self-care, and supportive policies from public health bodies all contribute to this trend. Patients prefer portable insulin delivery devices that simplify daily treatment routines and reduce hospital visits. Disposable insulin pens and wearable pumps, known for their convenience and reliability, are especially popular in home settings due to minimal training requirements.

North America Insulin Delivery Devices Market held 41.6% share in 2024, driven by a high diabetes prevalence, advanced healthcare infrastructure, and strong regulatory backing. The region's healthcare systems emphasize precision, safety, and user-friendliness, which makes insulin pens the favored choice in both inpatient and outpatient settings. The widespread availability of these devices through hospital pharmacies, retail outlets, and online platforms, combined with insurance coverage and government support, further accelerates adoption.

Key players in the Insulin Delivery Devices Market include Biocon, Novo Nordisk, Becton Dickinson and Company, Medtronic plc, Eli Lilly & Company, Insulet Corporation, Terumo Corporation, B. Braun Melsungen AG, Sanofi, Haselmeier, Ypsomed Holdings, Dongbao Pharmaceutical, Julphar, Tandem Diabetes Care, Owen Mumford, ViCentra B.V., Scientific Corporation, Debiotech S.A., Nipro Corporation, Gan & Lee Pharmaceuticals, Suzhou Peng Ye Medical Devices, Pacetronix, and MicroPort. Companies in the insulin delivery devices market focus on several core strategies to strengthen their market position and expand their global footprint. Continuous investment in research and development is crucial, enabling the launch of innovative products with enhanced usability, safety, and connectivity features such as AI-powered dosing and remote monitoring. Expanding distribution channels, including partnerships with healthcare providers, pharmacies, and digital health platforms, helps improve product accessibility worldwide.

Chapter 1 Methodology and Scope

1.1 Market scope and definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Data mining sources
- 1.3.1 Global
- 1.3.2 Regional/country
1.4 Base estimates and calculations
- 1.4.1 Base year calculation
- 1.4.2 Key trends for market estimation
1.5 Primary research and validation
- 1.5.1 Primary sources
1.6 Forecast model
1.7 Research assumptions and limitations

Chapter 2 Executive Summary

2.1 Industry 360° synopsis
2.2 Key market trends
- 2.2.1 Regional trends
- 2.2.2 Product trends
- 2.2.3 End use trends
2.3 CXO perspectives: Strategic imperatives
- 2.3.1 Key decision points for industry executives
- 2.3.2 Critical success factors for market players
2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
- 3.1.1 Supplier landscape
- 3.1.2 Factors affecting the value chain
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of diabetes
  - 3.2.1.2 Technological advancements in insulin delivery devices
  - 3.2.1.3 Increasing diabetes care expenditure
  - 3.2.1.4 Favourable device insurance and reimbursement policies
  - 3.2.1.5 Adoption of facilitative initiatives
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of insulin delivery devices
  - 3.2.2.2 High out-of-pocket expenditure in developing countries
  - 3.2.2.3 Stringent government regulations
- 3.2.3 Market opportunities
- 3.2.4 Integration with digital health platforms
- 3.2.5 Development of smart and wearable devices
3.3 Growth potential analysis
3.4 Regulatory landscape
- 3.4.1 North America
- 3.4.2 Europe
- 3.4.3 Asia Pacific
- 3.4.4 Latin America
- 3.4.5 Middle East and Africa
3.5 Technology landscape
- 3.5.1 Current technological trends
- 3.5.2 Emerging technologies
3.6 Future market trends
3.7 Pricing analysis, 2024
3.8 Patent analysis
3.9 Reimbursement scenario
3.10 Porter's analysis
3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

4.1 Introduction
4.2 Company market share analysis
- 4.2.1 Global
- 4.2.2 North America
- 4.2.3 Europe
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Key developments
- 4.6.1 Merger and acquisition
- 4.6.2 Partnership and collaboration
- 4.6.3 New product launches
- 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

5.1 Key trends
5.2 Insulin delivery devices
- 5.2.1 Insulin pumps
  - 5.2.1.1 Tubed pumps
  - 5.2.1.2 Tubeless pumps
- 5.2.2 Pens
  - 5.2.2.1 Reusable
  - 5.2.2.2 Disposable
- 5.2.3 Other insulin delivery devices
5.3 Consumables
- 5.3.1 Testing strips
- 5.3.2 Pen needles
  - 5.3.2.1 Standard
  - 5.3.2.2 Safety
- 5.3.3 Syringes
- 5.3.4 Insulin pumps consumables

Chapter 6 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

6.1 Key trends
6.2 Hospitals and Clinics
6.3 Home care
6.4 Other end users

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

7.1 Key trends
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
7.3 Europe
- 7.3.1 Germany
- 7.3.2 UK
- 7.3.3 France
- 7.3.4 Spain
- 7.3.5 Italy
- 7.3.6 Netherlands
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 India
- 7.4.3 Japan
- 7.4.4 Australia
- 7.4.5 South Korea
7.5 Latin America
- 7.5.1 Brazil
- 7.5.2 Mexico
- 7.5.3 Argentina
7.6 Middle East and Africa
- 7.6.1 South Africa
- 7.6.2 Saudi Arabia
- 7.6.3 UAE